Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity.

[1]  J. Shimizu,et al.  Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. , 2000, International immunology.

[2]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[3]  Fiona Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.

[4]  S. Sakaguchi.  Regulatory T cells , 2000, Cell.

[5]  J. Bluestone,et al.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.

[6]  Ethan M. Shevach,et al.  Suppressor Effector Function of CD4+CD25+ Immunoregulatory T Cells Is Antigen Nonspecific , 2000, The Journal of Immunology.

[7]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[8]  F. Otsuka,et al.  Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. , 1999, Journal of immunology.

[9]  M. Toda,et al.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.

[10]  W. van Eden,et al.  Anergic T cells actively suppress T cell responses via the antigen‐presenting cell , 1998, European journal of immunology.

[11]  E. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[12]  A. Abbas,et al.  Homeostasis and self-tolerance in the immune system: turning lymphocytes off. , 1998, Science.

[13]  C. Benoist,et al.  Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes , 1998, The Journal of experimental medicine.

[14]  E. Shevach,et al.  CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. , 1998, Journal of immunology.

[15]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[16]  J. Allison,et al.  The emerging role of CTLA-4 as an immune attenuator. , 1997, Immunity.

[17]  J. Bluestone.  Is CTLA-4 a master switch for peripheral T cell tolerance? , 1997, Journal of immunology.

[18]  A. Houghton,et al.  Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. June,et al.  CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. , 1996, Journal of immunology.

[20]  S. Sakaguchi,et al.  Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation , 1996, The Journal of experimental medicine.

[21]  R. Coffman,et al.  A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells , 1996, The Journal of experimental medicine.

[22]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[23]  A. Coutinho,et al.  A Model for Developmentally Acquired Thymus‐Dependent Tolerance to Central and Peripheral Antigens , 1996, Immunological reviews.

[24]  K. Inaba,et al.  Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity , 1996, The Journal of experimental medicine.

[25]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[26]  E. Sercarz,et al.  Induction of anti-self-immunity to cure cancer , 1995, Cell.

[27]  H. Weiner,et al.  Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. , 1994, Science.

[28]  R. Lechler,et al.  Anergic T cells as suppressor cells in vitro. , 1994, Science.

[29]  S. Koyasu,et al.  CD3+CD16+NK1.1+B220+ large granular lymphocytes arise from both alpha- beta TCR+CD4-CD8- and gamma-delta TCR+CD4-CD8- cells , 1994, The Journal of experimental medicine.

[30]  K. Tung,et al.  Tolerance mechanism in experimental ovarian and gastric autoimmune diseases. , 1992, Journal of immunology.

[31]  D. Mason,et al.  Subsets of CD4+ T Cells and their Roles in the Induction and Prevention of Autoimmunity , 1991, Immunological reviews.

[32]  D. Mason,et al.  OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset [published erratum appears in J Exp Med 1991 Apr 1;173(4):1037] , 1990, The Journal of experimental medicine.

[33]  D. Greiner,et al.  Adoptive transfer of autoimmune diabetes and thyroiditis to athymic rats. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Boitard,et al.  T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice , 1989, The Journal of experimental medicine.

[35]  M. Awwad,et al.  Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell- mediated immunity , 1988, The Journal of experimental medicine.

[36]  Y. Kohno,et al.  Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis. , 1988, Journal of immunology.

[37]  K. Kuribayashi,et al.  Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease , 1985, The Journal of experimental medicine.

[38]  E. Shevach,et al.  The murine IL 2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. , 1984, Journal of immunology.

[39]  R. North.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.

[40]  M. Greene,et al.  Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. , 1976, Journal of immunology.

[41]  E. Shevach.  Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.

[42]  S. Sakaguchi,et al.  Role of genetic factors in organ-specific autoimmune diseases induced by manipulating the thymus or T cells, and not self-antigens. , 2000, Reviews in immunogenetics.

[43]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[44]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[45]  V. Maino,et al.  Restricted expression of p55 interleukin 2 receptor (CD25) on normal T cells. , 1990, Clinical immunology and immunopathology.

[46]  S. Rosenberg,et al.  Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes , 1986 .

[47]  I. Bernard,et al.  Transforming Growth Factor (cid:98) (TGF- (cid:98) )-dependent Inhibition of T Helper Cell 2 (Th2)-induced Autoimmunity by Self–Major Histocompatibility Complex (MHC) Class II–specific, Regulatory CD4 (cid:49) T Cell Lines , 2022 .